Track topics on Twitter Track topics that are important to you
BOSTON — Sequential therapy with 1 mg ALG-1001 yielded equivalent visual acuity gains as treatment with bevacizumab monotherapy in patients with diabetic macular edema, according to a study presented here.“The safety profile was excellent. There was very little in the way of [serious adverse events] at all,” David Boyer, MD, said at the American Society of Retina Specialists meeting, where he delivered topline results for the phase 2 stage 2 DEL MAR study.NEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...